T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients

Wěi Li(Shougang (China)), Gerald Schmid‐Bindert(Heidelberg University), Jingyun Shi(Tongji University), Aiwu Li(Tongji University), Yayi He(Helix (United States)), Xuefei Li(Harbin Medical University), Shuai Li(Second Hospital of Tianjin Medical University), Jiayu Li(Tongji University), Lihong Fan(Wuhan University of Technology), Ke Fei(Tongji University), Xiaoxia Chen(Guangdong Academy of Medical Sciences), Cao Zhao(Tongji University), Shengxiang Ren(Tongji University), Guanghui Gao(Tongji University), Caicun Zhou(Tongji University)
Lung Cancer
March 20, 2014
10.1016/j.lungcan.2014.03.011
Cited by 94

Related Papers

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
HIF-1α pathway: role, regulation and intervention for cancer therapy
|Acta Pharmaceutica Sinica B|2015|1.9k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|504